Clinical trial
Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy
NCT00312780 · Symphony Evolution, Inc., Industry · Completed
Key facts
| NCT number | NCT00312780 |
|---|---|
| Title | Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Study of XL784 Administered Orally to Subjects With Albuminuria Due to Diabetic Nephropathy |
| Lead sponsor | Symphony Evolution, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Albuminuria, Diabetic Nephropathy |
| Intervention type | Drug |
| Interventions | XL784 |
| Enrollment | 125 |
| Start date | Mar 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Apr 11, 2006 |
| Last update posted | Feb 23, 2010 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: